Setting

Europe Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity

Published: 28 Apr 2021 | Report Code: 10247993 | Pages: 113

Europe small molecule active pharmaceutical ingredient (API) market accounted for $38.35 billion in 2020 and will grow by 7.7% annually over 2020-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic. Highlighted with 36 tables and 53 figures, this 113-page report “Europe Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country. Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Synthetic API o Branded Synthetic API o Generic Synthetic API • Semi-synthetic API • Natural Origin Based on Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Standard API • High Potency API (HPAPI) o Branded HPAPI o Generic HPAPI Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Applications Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. o Clinical Use o Commercial Use Based on Manufacturer Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Pharmaceutical Companies • CMOs Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Aurobindo Pharma Ltd. Cambrex Corporation Catalent, Inc. Dr. Reddy's Laboratories Ltd. GlaxoSmithKline plc Lonza Group Merck & Co., Inc. Mylan N.V. Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Wuxi AppTec Co., Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 14 1.2.6 Market Size/Share Estimation 15 1.2.7 Research Limitations 16 1.3 Executive Summary 17 2 Market Overview and Dynamics 20 2.1 Market Size and Forecast 20 2.1.1 Impact of COVID-19 on World Economy 21 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 28 2.4 Emerging Opportunities and Market Trends 31 2.5 Porter’s Fiver Forces Analysis 35 3 Segmentation of Europe Market by Source 39 3.1 Market Overview by Source 39 3.2 Synthetic API 41 3.2.1 Branded Synthetic API 42 3.2.2 Generic Synthetic API 43 3.3 Semi-synthetic API 44 3.4 Natural Origin 45 4 Segmentation of Europe Market by Type 46 4.1 Market Overview by Type 46 4.2 Standard API 48 4.3 High Potency API (HPAPI) 49 4.3.1 Branded HPAPI 50 4.3.2 Generic HPAPI 51 5 Segmentation of Europe Market by Therapeutic Area 52 5.1 Market Overview by Therapeutic Area 52 5.2 Infectious Diseases 54 5.3 Oncology 55 5.4 Ophthalmology 56 5.5 Cardiovascular Disorders 57 5.6 Central Nervous System 58 5.7 Respiratory Disorders 59 5.8 Metabolic Diseases 60 5.9 Other Applications 61 6 Segmentation of Europe Market by Application 62 6.1 Market Overview by Application 62 6.2 Clinical Use 64 6.3 Commercial Use 65 7 Segmentation of Europe Market by Manufacturer Type 66 7.1 Market Overview by Manufacturer Type 66 7.2 Pharmaceutical Companies 68 7.3 CMOs 70 8 European Market 2020-2027 by Country 72 8.1 Overview of European Market 72 8.2 UK 75 8.3 France 77 8.4 Germany 79 8.5 Spain 81 8.6 Italy 83 8.7 Russia 85 8.8 Rest of European Market 87 9 Competitive Landscape 89 9.1 Overview of Key Vendors 89 9.2 New Product Launch, Partnership, Investment, and M&A 92 9.3 Company Profiles 93 Aurobindo Pharma Ltd. 93 Cambrex Corporation 95 Catalent, Inc. 96 Dr. Reddy's Laboratories Ltd. 97 GlaxoSmithKline plc 98 Lonza Group 99 Merck & Co., Inc. 100 Mylan N.V. 101 Novartis AG 102 Pfizer Inc. 103 Sun Pharmaceutical Industries Ltd. 104 Teva Pharmaceutical Industries Ltd. 105 Wuxi AppTec Co., Ltd. 106 10 Investing in Europe Market: Risk Assessment and Management 107 10.1 Risk Evaluation of Europe Market 107 10.2 Critical Success Factors (CSFs) 110 Related Reports and Products 113
List Of Tables

Table 1. Snapshot of Europe Small Molecule API Market in Balanced Perspective, 2020-2027 18 Table 2. Growth Rate of World GDP, 2020-2022 22 Table 3. Main Product Trends and Market Opportunities in Europe Small Molecule API Market 31 Table 4. Europe Small Molecule API Market by Source, 2017-2027, $ mn 39 Table 5. Europe Small Molecule API Market: Synthetic API by Drug Type, 2017-2027, $ mn 41 Table 6. Europe Small Molecule API Market by Type, 2017-2027, $ mn 46 Table 7. Europe Small Molecule API Market: HPAPI by Drug Type, 2017-2027, $ mn 49 Table 8. Europe Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 52 Table 9. Europe Small Molecule API Market by Application, 2017-2027, $ mn 62 Table 10. Europe Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 66 Table 11. Europe Small Molecule API Market by Country, 2017-2027, $ mn 74 Table 12. UK Small Molecule API Market by Type, 2017-2027, $ mn 76 Table 13. UK Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 76 Table 14. UK Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 76 Table 15. France Small Molecule API Market by Type, 2017-2027, $ mn 78 Table 16. France Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 78 Table 17. France Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 78 Table 18. Germany Small Molecule API Market by Type, 2017-2027, $ mn 80 Table 19. Germany Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 80 Table 20. Germany Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 80 Table 21. Spain Small Molecule API Market by Type, 2017-2027, $ mn 82 Table 22. Spain Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 82 Table 23. Spain Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 82 Table 24. Italy Small Molecule API Market by Type, 2017-2027, $ mn 84 Table 25. Italy Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 84 Table 26. Italy Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 84 Table 27. Russia Small Molecule API Market by Type, 2017-2027, $ mn 86 Table 28. Russia Small Molecule API Market by Therapeutic Area, 2017-2027, $ mn 86 Table 29. Russia Small Molecule API Market by Manufacturer Type, 2017-2027, $ mn 86 Table 30. Small Molecule API Market in Rest of Europe by Country, 2017-2027, $ mn 88 Table 31. Aurobindo Pharma Ltd.: Company Snapshot 93 Table 32. Aurobindo Pharma Ltd.: Business Segmentation 93 Table 33. Aurobindo Pharma Ltd.: Product Portfolio 94 Table 34. Aurobindo Pharma Ltd.: Revenue, 2017-2019, $ mn 94 Table 35. Risk Evaluation for Investing in Europe Market, 2020-2027 108 Table 36. Critical Success Factors and Key Takeaways 111
List Of Figures

Figure 1. Research Method Flow Chart 11 Figure 2. Breakdown of Primary Research 13 Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15 Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17 Figure 5. Europe Small Molecule API Market, 2017-2027, $ mn 20 Figure 6. Impact of COVID-19 on Business 23 Figure 7. Primary Drivers and Impact Factors of Europe Small Molecule API Market 25 Figure 8. Primary Restraints and Impact Factors of Europe Small Molecule API Market 28 Figure 9. Investment Opportunity Analysis 32 Figure 10. Porter’s Fiver Forces Analysis of Europe Small Molecule API Market 35 Figure 11. Breakdown of Europe Small Molecule API Market by Source, 2020-2027, % of Revenue 39 Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Source, Value ($ mn) and Share (%) 40 Figure 13. Europe Small Molecule API Market: Synthetic API, 2017-2027, $ mn 41 Figure 14. Europe Small Molecule API Market: Branded Synthetic API, 2017-2027, $ mn 42 Figure 15. Europe Small Molecule API Market: Generic Synthetic API, 2017-2027, $ mn 43 Figure 16. Europe Small Molecule API Market: Semi-synthetic API, 2017-2027, $ mn 44 Figure 17. Europe Small Molecule API Market: Natural Origin, 2017-2027, $ mn 45 Figure 18. Breakdown of Europe Small Molecule API Market by Type, 2020-2027, % of Revenue 46 Figure 19. Contribution to Europe 2021-2027 Cumulative Revenue by Type, Value ($ mn) and Share (%) 47 Figure 20. Europe Small Molecule API Market: Standard API, 2017-2027, $ mn 48 Figure 21. Europe Small Molecule API Market: High Potency API (HPAPI), 2017-2027, $ mn 49 Figure 22. Europe Small Molecule API Market: Branded HPAPI, 2017-2027, $ mn 50 Figure 23. Europe Small Molecule API Market: Generic HPAPI, 2017-2027, $ mn 51 Figure 24. Breakdown of Europe Small Molecule API Market by Therapeutic Area, 2020-2027, % of Revenue 53 Figure 25. Contribution to Europe 2021-2027 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%) 53 Figure 26. Europe Small Molecule API Market: Infectious Diseases, 2017-2027, $ mn 54 Figure 27. Europe Small Molecule API Market: Oncology, 2017-2027, $ mn 55 Figure 28. Europe Small Molecule API Market: Ophthalmology , 2017-2027, $ mn 56 Figure 29. Europe Small Molecule API Market: Cardiovascular Disorders, 2017-2027, $ mn 57 Figure 30. Europe Small Molecule API Market: Central Nervous System, 2017-2027, $ mn 58 Figure 31. Europe Small Molecule API Market: Respiratory Disorders, 2017-2027, $ mn 59 Figure 32. Europe Small Molecule API Market: Metabolic Diseases, 2017-2027, $ mn 60 Figure 33. Europe Small Molecule API Market: Other Applications, 2017-2027, $ mn 61 Figure 34. Breakdown of Europe Small Molecule API Market by Application, 2020-2027, % of Revenue 62 Figure 35. Contribution to Europe 2021-2027 Cumulative Revenue by Application, Value ($ mn) and Share (%) 63 Figure 36. Europe Small Molecule API Market: Clinical Use, 2017-2027, $ mn 64 Figure 37. Europe Small Molecule API Market: Commercial Use, 2017-2027, $ mn 65 Figure 38. Breakdown of Europe Small Molecule API Market by Manufacturer Type, 2020-2027, % of Revenue 66 Figure 39. Contribution to Europe 2021-2027 Cumulative Revenue by Manufacturer Type, Value ($ mn) and Share (%) 67 Figure 40. Europe Small Molecule API Market: Pharmaceutical Companies, 2017-2027, $ mn 68 Figure 41. Breakdown of Europe Small Molecule API In-house Synthesis Market by Region, 2020-2027, % of Revenue 69 Figure 42. Europe Small Molecule API Market: CMOs, 2017-2027, $ mn 70 Figure 43. Breakdown of Europe Small Molecule API Contract Synthesis Market by Region, 2020-2027, % of Revenue 71 Figure 44. Breakdown of European Small Molecule API Market by Country, 2020 and 2027, % of Revenue 73 Figure 45. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 74 Figure 46. Small Molecule API Market in UK, 2017-2027, $ mn 75 Figure 47. Small Molecule API Market in France, 2017-2027, $ mn 77 Figure 48. Small Molecule API Market in Germany, 2017-2027, $ mn 79 Figure 49. Small Molecule API Market in Spain, 2017-2027, $ mn 81 Figure 50. Small Molecule API Market in Italy, 2017-2027, $ mn 83 Figure 51. Small Molecule API Market in Russia, 2017-2027, $ mn 85 Figure 52. Small Molecule API Market in Rest of Europe, 2017-2027, $ mn 87 Figure 53. Growth Stage of Europe Small Molecule API Industry over the Forecast Period 89
Key Players (this may not be a complete list and extra companies can be added upon request): 
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent, Inc.
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)